Julie Krystal / Northwell Health (sponsor), 2026-08-06: Registry record for a phase 1/2 pediatric glioma trial at Cohen Children's Medical Center testing mebendazole with standard chemotherapy. It lists 10 actual enrollees and is active but not recruiting.
Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.
n/a
Julie Krystal / Northwell Health (sponsor), 2026-08-06: Registry record for a phase 1/2 pediatric glioma trial at Cohen Children's Medical Center testing mebendazole with standard chemotherapy. It lists 10 actual enrollees and is active but not recruiting. Record field quoted from the arm description; registry record. Study type: phase 1/2, two-arm. N=10 actual. Country: United States. Dose: mebendazole oral twice daily continuously; low-grade arm with carboplatin/vincristine/temozolomide for seven 10-week cycles; high-grade arm with bevacizumab 10 mg/kg/dose and irinotecan 150 mg/m2/dose every 28 days for twelve cycles. Sponsor: Julie Krystal (Northwell Health); collaborator Janssen. Status: ACTIVE_NOT_RECRUITING; start 2013-10-22; estimated completion 2027-12. hasResults=false. Comparator: historical/standard chemotherapy backbone, no placebo. Results published by Krystal et al. 2024 (MBC-13). Registry entry; no results posted.
